Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. (October 2018)

• Record Type: Journal Article
• Authors: Salvador-Martín, Sara; García-González, Xandra; García, María I.; Blanco, Carolina; García-Alfonso, Pilar; Robles, Luis; Grávalos, Cristina; Pachón, Vanessa; Longo, Federico; Martínez, Virginia; Sanjurjo-Sáez, María; López-Fernández, Luis A.
• Is Part Of: Pharmacological research. Volume 136(2018)
• Page Start: 133
• Page End: 139
• Publication Date: 2018-10
• Subjects: Adverse reactions -- Pharmacogenetics -- SNP -- Cancer -- UGT1A1 -- ABC transporters; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2018.08.026
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Preventing severe irinotecan-induced adverse reactions would allow us to offer better treatment and improve patients' quality of life. Transporters, metabolizing enzymes, and genes involved in the folate pathway have been associated with irinotecan-induced toxicity. We analyzed 12 polymorphisms in UGT1A1, ABCB1, ABCG2, ABCC4, ABCC5, and MTHFR in 158 patients with metastatic colorectal cancer treated with irinotecan and studied the association with grade >2 adverse reactions (CTCAE). Among the most frequent ADRs, the SNPs rs1128503, rs2032582, and rs1045642 in ABCB1 and rs1801133 in MTHFR were associated with hematological toxicity and overall toxicity. The SNP rs11568678 in ABCC4 was also associated with overall toxicity. After correction of P values using a false discovery rate, only ABCB1 variants remained statistically significant. Haplotype analysis in ABCB1 showed an 11.3-fold and 4.6-fold increased risk of hematological toxicity (95% CI, 1.459–88.622) and overall toxicity (95% CI, 2.283–9.386), respectively. Consequently, genotyping of the three SNPs in ABCB1 can predict overall toxicity and hematological toxicity with a diagnostic odds ratio of 4.40 and 9.94, respectively. Genotyping of ABCB1 variants can help to prevent severe adverse reactions to irinotecan-based treatments in colorectal cancer.